DeepMed Research

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Safety and Efficacy of Oral Etrasimod in Adult Participants With Moderate-to-Severe Alopecia Areata

Phase 2

Completed

Conditions: Alopecia Areata

Interventions: Drug: Etrasimod
Drug: Placebo

First Posted Date: 2020-09-21

Last Posted Date: 2024-06-26

Lead Sponsor: Pfizer

Target Recruit Count: 80

Registration Number: NCT04556734

Locations: 🇺🇸
UPMC Department of Dermatology, Pittsburgh, Pennsylvania, United States
🇺🇸
UPMC Eye Center, Pittsburgh, Pennsylvania, United States
🇺🇸
Investigate MD, Scottsdale, Arizona, United States

and more 39 locations

Axitinib Therapy Management Study

Withdrawn

Conditions: Renal Cell Carcinoma

First Posted Date: 2020-09-18

Last Posted Date: 2023-11-21

Lead Sponsor: Pfizer

Registration Number: NCT04555603

Locations: 🇺🇸
Pfizer Inc., New York, New York, United States

PF-07104091 as a Single Agent and in Combination Therapy

Phase 1

Active, not recruiting

Conditions: Breast Cancer
Small Cell Lung Cancer
Ovarian Cancer

Interventions: Drug: PF-07104091 monotherapy dose escalation
Drug: PF-0704091 + Fulvestrant (post CDK4/6)
Drug: PF-07104091 + palbociclib + fulvestrant
Drug: PF-07104091 + palbociclib + letrozole
Drug: PF-07104091 monotherapy dose expansion (SCLC)
Drug: PF-07104091 monotherapy dose expansion (ovarian)
Drug: PF-07104091 + Fulvestrant (post CDK4/6)

First Posted Date: 2020-09-17

Last Posted Date: 2024-05-16

Lead Sponsor: Pfizer

Target Recruit Count: 154

Registration Number: NCT04553133

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇨🇳
Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China

and more 46 locations

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06882961 in Japanese Adults With Type 2 Diabetes Mellitus

Phase 1

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Placebo
Drug: PF-06882961

First Posted Date: 2020-09-17

Last Posted Date: 2022-03-11

Lead Sponsor: Pfizer

Target Recruit Count: 37

Registration Number: NCT04552470

Locations: 🇯🇵
P-one clinic, Keikokai medical corporation, Hachioji, Tokyo, Japan

Patterns of Real-World Isavuconazole Use - a Study of Patients With Mucormycosis or Invasive Aspergillosis

Completed

Conditions: Invasive Aspergillosis
Mucormycosis

First Posted Date: 2020-09-16

Last Posted Date: 2024-03-19

Lead Sponsor: Pfizer

Target Recruit Count: 307

Registration Number: NCT04550936

Locations: 🇫🇷
Hôpital Huriez CHU de Lille, Lille, France
🇫🇷
Institut de Cancérologie, Strasbourg, France
🇫🇷
CHU de Limoges, Limoges, France

and more 13 locations

Bioequivalence Study of Bosutinib Pediatric Capsule Relative to Commercial Tablet Under Fed Condition

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: Bosutinib tablet
Drug: Bosutinib capsule

First Posted Date: 2020-09-16

Last Posted Date: 2022-02-16

Lead Sponsor: Pfizer

Target Recruit Count: 66

Registration Number: NCT04549480

Locations: 🇳🇱
PRA Health Sciences Utrecht, Utrecht, Netherlands
🇳🇱
PRA Health Sciences, Groningen, Netherlands

20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 3-Dose Series in Healthy Infants

Phase 3

Completed

Conditions: Pneumococcal Disease

Interventions: Biological: 20-valent pneumococcal conjugate vaccine
Biological: 13-valent pneumococcal conjugate vaccine

First Posted Date: 2020-09-14

Last Posted Date: 2024-01-08

Lead Sponsor: Pfizer

Target Recruit Count: 1258

Registration Number: NCT04546425

Locations: 🇦🇺
Perth Children's Hospital, Nedlands, Western Australia, Australia
🇦🇺
Telethon Kids Institute, Vaccine Trials Group, Perth Children's Hospital, Nedlands, Western Australia, Australia
🇧🇪
Cliniques Universitaires Saint-Luc, Brussels, Belgium

and more 63 locations

Study To Evaluate The Pharmacokinetic, Safety And Tolerability Of Single Or Multiple Subcutaneous Doses of Recifercept

Phase 1

Completed

Conditions: Healthy

Interventions: Other: Placebo
Drug: Recifercept

First Posted Date: 2020-09-10

Last Posted Date: 2022-01-10

Lead Sponsor: Pfizer

Target Recruit Count: 24

Registration Number: NCT04543344

Locations: 🇧🇪
Brussels Clinical Research Unit, Brussels, Bruxelles-capitale, Région DE, Belgium

A Study to Evaluate AAV9 Neutralizing Antibody Seroconversion in Household Contacts.

Terminated

Conditions: Household Contacts

Interventions: Other: Blood Draw

First Posted Date: 2020-09-10

Last Posted Date: 2025-02-26

Lead Sponsor: Pfizer

Target Recruit Count: 8

Registration Number: NCT04543357

Locations: 🇺🇸
Kennedy Krieger Institute, Baltimore, Maryland, United States

A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement

Phase 1

Terminated

Conditions: Brain Neoplasms, Primary
Malignant Neoplasms
Malignant Melanoma
Brain Neoplasms
Carcinoma, Non-Small-Cell Lung

Interventions: Drug: PF-07284890
Drug: Binimetinib
Drug: Midazolam

First Posted Date: 2020-09-10

Last Posted Date: 2024-05-22

Lead Sponsor: Pfizer

Target Recruit Count: 66

Registration Number: NCT04543188

Locations: 🇺🇸
Northwestern Memorial Hospital, Chicago, Illinois, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 73 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy